Compare ALTI & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | CADL |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | United States |
| Employees | 490 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 409.8M | 578.8M |
| IPO Year | 2021 | 2021 |
| Metric | ALTI | CADL |
|---|---|---|
| Price | $2.94 | $8.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 220.8K | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.11 | ★ 58.62 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $254,956,000.00 | $125,000.00 |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $10.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.75 | $4.35 |
| 52 Week High | $5.45 | $9.57 |
| Indicator | ALTI | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 55.87 |
| Support Level | N/A | $4.80 |
| Resistance Level | $3.93 | $9.42 |
| Average True Range (ATR) | 0.18 | 0.61 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 25.76 | 37.20 |
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.